Background Image
Menu

Latest News

Monument Therapeutics announces first patient dosed in clinical trial of MT1988 in patients at clinical high risk for psychosis

10 March 2026

Monument Therapeutics announces first patient dosed in clinical trial of MT1988 in patients at clinical high risk for psychosis

Manchester, UK, March 10, 2026 - Monument Therapeutics, a stratified medicine company, today announced that the first patient has been dosed in its proof-of-principle clinical trial with MT1988 in patients at clinical high risk (CHR) for psychosis. The study is being conducted...

Biofortuna pioneers new robotic system for diagnostic tests

23 February 2026

Biofortuna pioneers new robotic system for diagnostic tests

A North Wales biotechnology company has developed a new robotic dispensing system designed to improve the production of diagnostic testing devices used to detect conditions including cancer.  Deeside-based Biofortuna secured £225,000 through the Welsh Government’s SMART Flexible...

Proveca announces exclusive worldwide development and license agreement with Catalent for its Zydis® ODT technology for use with Glycopyrrolate

11 February 2026

Proveca announces exclusive worldwide development and license agreement with Catalent for its Zydis® ODT technology for use with Glycopyrrolate

This press release is intended for investors only. 10th February 2026 - Proveca, a pharmaceutical company specialising in medicines for children, announced today that it has entered into an exclusive worldwide development and license agreement with Catalent, a leading global...

QV Bioelectronics receives £4.5m boost for implantable brain cancer therapy

21 January 2026

QV Bioelectronics receives £4.5m boost for implantable brain cancer therapy

A Cheshire-based medtech business has secured £4.5m of investment and grant funding to revolutionise treatment for the most common type of primary brain cancer in adults. The investment round was led by PXN Ventures, which launched following the merger between Praetura Ventures...

Oxford BioTherapeutics enters into strategic collaboration with GSK to discover novel targets for antibody-based therapeutics for the treatment of cancer

10 December 2025

Oxford BioTherapeutics enters into strategic collaboration with GSK to discover novel targets for antibody-based therapeutics for the treatment of cancer

• Collaboration leverages OBT's proprietary OGAP®-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology targets … • The agreement - OBT's second high-profile pharma collaboration this year - reflects the strong validation of...

Welsh Government Ministers visit Biofortuna to celebrate innovation and skills development

9 December 2025

Welsh Government Ministers visit Biofortuna to celebrate innovation and skills development

Biofortuna, a leading diagnostics manufacturer and laboratory services provider, welcomed Welsh Government Ministers Ken Skates MS and Jack Sargeant MS on Monday (8th December) to demonstrate how the Deeside-based CDMO is playing a pivotal role in the early detection of disease.

MAXWELLIA - Pharmacist and ‘OTC innovator’ named North West Innovation Entrepreneur of the Year

24 November 2025

MAXWELLIA - Pharmacist and ‘OTC innovator’ named North West Innovation Entrepreneur of the Year

Pharmacist and founder of healthcare brand Maxwellia, Anna Maxwell, has been named Innovation Entrepreneur of the Year for the North West at the Great British Entrepreneur Awards.  Her work involves ‘switching’ UK prescription (Rx) medicines to launch as over the counter (OTC)...

New prescription-strength pain relief hits high street chemists, hailed as ‘game-changer’ by pharmacists

13 October 2025

New prescription-strength pain relief hits high street chemists, hailed as ‘game-changer’ by pharmacists

Alderley Park, Cheshire, UK – A new anti-inflammatory pain relief treatment available from pharmacies, is being described as a ‘game-changer’ for the millions of people who suffer short-term back, muscle and joint pain every year in the UK.  … Naprosyn® Pain Relief is the first...

Pencil Biosciences appoints Jonathan Thon, PhD, as Chair of the Board of Directors

16 September 2025

Pencil Biosciences appoints Jonathan Thon, PhD, as Chair of the Board of Directors

Cheshire, UK – September 15, 2025 – Pencil Biosciences, a biotech company pioneering a new class of gene editor, today announced the appointment of Jonathan Thon, PhD, as the new Chair of its Board of Directors. The company’s novel platform, which offers “break-free editing” and...

The Biorenewables Development Centre partners with CroBio on Engineering Biology Award to tackle water scarcity

15 September 2025

The Biorenewables Development Centre partners with CroBio on Engineering Biology Award to tackle water scarcity

The Biorenewables Development Centre (BDC) and UK-based biotech company CroBio have secured an Engineering Biology SPARK Award from InnovateUK. This funding will support a collaborative project aimed at developing a non-genetically modified (non-GM) microbial soil amendment to...